ONE MAIN STREET, CAMBRIDGE, MA
Market cap: $571.9M (12/18/2025)
Price: $9.68
Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
Cullinan Therapeutics Terminates Exclusive Patent License Agreement with MIT
Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Cullinan Therapeutics Presents CLN-049 Clinical Activity in AML at ASH
Investor Presentation
Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Shareholder votes
Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases, Investor Presentation
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence